US 12,168,692 B1
Antibodies targeting CCR2
Matthias Mack, Regensburg (DE)
Assigned to Granite Bio AG, Basel (CH)
Filed by GRANITE BIO AG, Basel (CH)
Filed on Aug. 2, 2024, as Appl. No. 18/793,279.
Application 18/793,279 is a continuation of application No. 18/700,201, previously published as PCT/EP2022/079744, filed on Oct. 25, 2022.
Int. Cl. C07K 16/00 (2006.01); C07K 16/28 (2006.01)
CPC C07K 16/2866 (2013.01) [C07K 2317/24 (2013.01)] 30 Claims
 
1. An antibody or antibody fragment that specifically binds to human CCR2, comprising a VH comprising HCDR1, HCDR2, and HCDR3, and a VL comprising LCDR1, LCDR2, and LCDR3, wherein the HCDR1, HCDR2, and HCDR3 comprise the HCDR1, HCDR2, and HCDR3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 22; and wherein the LCDR1, LCDR2, and LCDR3 comprise the LCDR1, LCDR2, and LCDR3 of the VL amino acid sequence set forth in SEQ ID NO: 23.